• Eylea faces increased competition, but is also benefiting from demographic tailwinds and additional line extensions. Future growth will depend on Beovu’s success.

• Dupixent is seeing strong adoption in atopic dermatitis driven by a differentiated clinical profile, and is being explored in numerous additional indications

• Investors are excited by REGN1979, which could challenge rituximab in non-Hodgkin’s Lymphoma. An update will be provided at ASH in early December

- Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years

- Eylea recently received approval for a 12 week dose, but with cautious language on the label, leaving the door open for competitors to potentially take share when they enter the market.

- Dupixent is a promising asset that could drive growth after Eylea, but will need to get past reimbursement issues and execute on indication expansions to stay ahead of competition.